John W Kozarich Ligand Pharmaceuticals Inc (LGND) insider trading activity

LGND Quotes by TradingView

John W Kozarich is Director of LIGAND PHARMACEUTICALS INC. Currently has a direct ownership of 44,121 shares of LGND, which is worth approximately $8.86 Million. The most recent transaction as insider was on Dec 01, 2025, when has been sold 467 shares (Common Stock) at a price of $196.82 per share, resulting in proceeds of $91,914. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 44.1K
3.08% 3M change
0.79% 12M change
Total Value Held $8.86 Million

JOHN W KOZARICH Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 01 2025
SELL
Open market or private sale
$91,914 $196.82 p/Share
467 Reduced 1.05%
44,121 Common Stock
Nov 03 2025
SELL
Open market or private sale
$89,066 $190.72 p/Share
467 Reduced 1.04%
44,588 Common Stock
Oct 01 2025
SELL
Open market or private sale
$83,733 $179.3 p/Share
467 Reduced 1.03%
45,055 Common Stock
Sep 02 2025
SELL
Open market or private sale
$76,008 $162.76 p/Share
467 Reduced 1.02%
45,522 Common Stock
Aug 01 2025
SELL
Open market or private sale
$61,587 $131.88 p/Share
467 Reduced 1.01%
45,989 Common Stock
Jul 10 2025
SELL
Open market or private sale
$116,750 $125.0 p/Share
934 Reduced 1.97%
46,456 Common Stock
Jun 06 2025
BUY
Grant, award, or other acquisition
-
1,209 Added 2.49%
47,390 Common Stock
Jan 17 2025
BUY
Exercise of conversion of derivative security
$125,833 $52.3 p/Share
2,406 Added 4.95%
46,181 Common Stock
Jun 14 2024
BUY
Grant, award, or other acquisition
-
1,252 Added 2.78%
43,775 Common Stock
Apr 24 2024
BUY
Exercise of conversion of derivative security
$113,839 $39.35 p/Share
2,893 Added 6.37%
42,523 Common Stock
Jun 09 2023
BUY
Grant, award, or other acquisition
-
1,142 Added 2.8%
39,630 Common Stock
May 16 2023
SELL
Open market or private sale
$343,076 $77.2 p/Share
4,444 Reduced 10.35%
38,488 Common Stock
May 08 2023
SELL
Open market or private sale
$492,198 $76.81 p/Share
6,408 Reduced 13.18%
42,213 Common Stock
May 08 2023
BUY
Exercise of conversion of derivative security
$120,598 $18.82 p/Share
6,408 Added 11.64%
48,621 Common Stock
Jun 10 2022
BUY
Grant, award, or other acquisition
-
1,004 Added 2.32%
42,213 Common Stock
Feb 28 2022
SELL
Open market or private sale
$93,179 $102.62 p/Share
908 Reduced 2.16%
41,209 Common Stock
Feb 28 2022
BUY
Exercise of conversion of derivative security
$91,908 $12.53 p/Share
7,335 Added 14.83%
42,117 Common Stock
Jun 04 2021
BUY
Grant, award, or other acquisition
-
630 Added 1.78%
34,782 Common Stock
May 11 2021
SELL
Payment of exercise price or tax liability
$50,267 $128.56 p/Share
391 Reduced 1.13%
34,152 Common Stock
May 11 2021
BUY
Exercise of conversion of derivative security
$48,930 $10.12 p/Share
4,835 Added 12.28%
34,543 Common Stock
Feb 22 2021
BUY
Exercise of conversion of derivative security
$25,300 $10.12 p/Share
2,500 Added 7.76%
29,708 Common Stock
JWK

John W Kozarich

Director
Emeryville, CA

Track Institutional and Insider Activities on LGND

Follow LIGAND PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LGND shares.

Notify only if

Insider Trading

Get notified when an Ligand Pharmaceuticals Inc insider buys or sells LGND shares.

Notify only if

News

Receive news related to LIGAND PHARMACEUTICALS INC

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on LGND